ArticleiScience2022

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers.

Yan-Ruide Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.